Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

EstoniaBack to Estonia

Clinical trials in Tallin – page 3

148 clinical trials in Tallin, Estonia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Tallin at a glance
148
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

148 trials in Tallin

Open in trial search

Major depression

Recruiting

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Major depression

Recruiting

Study of NBI-1065845 as add-on treatment to prevent depression relapse in adults with Major Depressive Disorder who responded to initial treatment

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Intensive care

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Rigshospitalet

Non-small cell lung cancer+4

Recruiting

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:ETOP IBCSG Partners Foundation

Plasma cell myeloma

Recruiting

Study of Selinexor, Bortezomib, and Lenalidomide with Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Odense University Hospital

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford

Psoriatic arthropathy

Recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Estonia

The busiest research cities in the country

All 11 cities in Estonia

Clinical research in Tallin

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on innovative treatments for ulcerative colitis, specifically targeting patients with mild to moderate left-sided manifestations of the condition. The research explores new therapeutic approaches using targeted delivery methods.

  • Inflammatory Bowel Disease Management
  • Novel Drug Delivery Systems
  • Gastrointestinal Therapeutics

These trials aim to evaluate the effectiveness of a new localized treatment approach compared to placebo, potentially offering improved options for patients with inflammatory bowel conditions.

Back to EstoniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.